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Background: One third of people diagnosed with schizophrenia fail to respond adequately to 
antipsychotic medication, resulting in persisting disabling symptoms, higher rates of 
hospitalisation and higher costs for society. In an effort to better understand the mechanisms 
behind resistance to antipsychotic treatment in schizophrenia, we investigated its potential 
relationship to the genetic architecture of the disorder. 
Methods: Patients diagnosed with a schizophrenia spectrum disorder (N=321) were classified 
as either being treatment-resistant (N=108) or non-treatment-resistant (N=213) to 
antipsychotic medication using defined consensus criteria. A schizophrenia polygenic risk 
score based on genome-wide association studies (GWAS) was calculated for each patient and 
binary logistic regression was performed to investigate the association between polygenetic 
risk and treatment resistance. We adjusted for principal components, batch number, age and 
sex. Additional analyses were performed to investigate associations with demographic and 
clinical variables. 
Results: High levels of polygenic risk score for schizophrenia significantly predicted 
treatment resistance (p=0.003). The positive predictive value of the model was 61.5% and the 
negative predictive value was 71.7%. The association was significant for one (p=0.01) out of 
five tested SNP significance thresholds. Season of birth was able to predict treatment-
resistance in the regression model (p=0.05).  
Conclusions: The study indicates that treatment-resistance to antipsychotic medication is 
associated with higher polygenetic risk of schizophrenia, suggesting a link between 
antipsychotics mechanism of action and the genetic underpinnings of the disorder. 
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Schizophrenia is a severe mental disorder that has a profound impact on affected individuals 
and imposes large economic costs on the society (Chong et al., 2016; Knapp et al., 2004).  
Schizophrenia is ranked amongst the most disabling disorders globally (Charlson et al., 2018), 
with recovery rates as low as 13.5 % (Jaaskelainen et al., 2013). The disorder is associated 
with a significant loss of productivity (Knapp et al., 2004) and a 10-20 years shorter life 
expectancy (Chesney et al., 2014). Antipsychotic drugs have become a cornerstone in the 
treatment of schizophrenia (Leucht et al., 2012). Although varying in targeted receptors 
(Kusumi et al., 2015), all antipsychotics share the property of regulating dopamine signalling 
(Amato et al., 2018). The efficacy in reducing symptoms differ only but little between the 
drugs (Leucht et al., 2013).  
Among individuals diagnosed with schizophrenia, about one third display treatment-
resistance (TR) (Elkis, 2007), with persisting disabling symptoms after adequate trials of 
antipsychotic drugs. Recently, the Treatment Response and Resistance in Psychosis (TRRIP) 
working group was established to solve difficulties in comparing studies, interpreting meta-
analyses and replicating research on TR, by standardizing the definition of TR (Howes et al., 
2017). Clozapine is a well-documented antipsychotic drug against treatment-refractory 
symptoms (Siskind et al., 2016), but due to its severe adverse effects, clinicians often restrain 
from prescribing this drug (Warnez and Alessi-Severini, 2014). Thus, many patients are being 
subjected to a trial-and-error testing of drugs with various troublesome side effects (Iversen et 
al., 2018), which adds to the burden of the disorder itself (Charlson et al., 2018). Moreover, 
patients with TR have more impaired functioning, poorer psychosocial adjustment, higher 
rates of hospitalization and represent a higher cost to society relative to antipsychotic-




Mapping predictors of antipsychotics response may take us closer to personalised medicine in 
schizophrenia (Lally et al., 2016; Lally and MacCabe, 2015). 
It has been suggested that TR might be a categorically distinct subgroup (Gillespie et al., 
2017) or represent the most severe cases on a continuum (Molent et al., 2019). MRI studies of 
the brain show that TR patients have lower grey matter volumes compared with both 
treatment responders and healthy volunteers (Anderson et al., 2015). Moreover, patients with 
TR seem to have lower levels of striatal dopamine synthesis capacity (Demjaha et al., 2012), 
as well as alterations in glutamate concentration (Demjaha et al., 2014) compared to treatment 
responders. In addition, patients with TR seem to have specific neurocognitive deficits (de 
Bartolomeis et al., 2013; Joober et al., 2002), and treatment response to their first 
antipsychotic trial, including lack of remission during the first three months, seems to predict 
long-term outcome of the disorder (Agid et al., 2011; Friis et al., 2016; Kolakowska et al., 
1985). It has also been hypothesized that patients with TR may share genetic underpinnings 
(Nucifora et al., 2019). This is further supported by findings showing that family members of 
patients with TR are more likely to have a diagnosis of schizophrenia in comparison with 
family members of responsive patients with schizophrenia (Hajj et al., 2019; Silverman et al., 
1987), indicating a common genetic component (Joober et al., 2005). Taken together, these 
findings indicate that TR might be at least partly determined by the burden of genetic risk for 
schizophrenia. 
Recent GWAS in schizophrenia have established a large number of single nucleotide 
polymorphisms (SNPs) associated with the disorder (Pardinas et al., 2018). This has enabled 
the generation of a schizophrenia polygenic risk score (PRS-SZ) (Tesli et al., 2014) 
representing the weighed genetic predisposition of an individual to the disorder. PRS is a new 
and promising genetic measure in psychiatry (Pardinas et al., 2018; Purcell et al., 2009) as 




SZ and TR in schizophrenia, however with conflicting results. Associations between PRS-SZ 
and a history of clozapine treatment (Frank et al., 2015) and lack of response to antipsychotics 
(Zhang et al., 2019) have been reported, suggesting that the genetics of schizophrenia is also 
involved in TR. Three other studies found no association between PRS-SZ and TR (Legge et 
al., 2019; Martin and Mowry, 2016; Wimberley et al., 2017). There are several possible 
explanations for the different results. There is a variation of strategies for selecting SNP 
thresholds and number of thresholds tested (Wimberley et al. 2017; Zhang et al. 2019; Legge 
et al. 2019). Moreover, various definitions of TR are applied (Wimberley et al. 2017; Frank et 
al. 2015). In the study by Zhang et al. (2019), antipsychotic efficacy was assessed based on 
symptom scores as opposed to studies specifically investigating TR (e.g. Frank et al. 2015). 
Also, samples vary between first episode patients and more chronic conditions as well as in 
methods of determining diagnoses (Zhang et al. 2019; Wimberley et al. 2017). Hence, the 
genetic architecture of TR is mainly unresolved. 
Efforts have been made to understand clinical correlates underlying biological mechanisms 
and predictive factors for TR (Nucifora et al., 2019; Wimberley et al., 2016). Clinical and 
demographic factors associated with TR include earlier age at onset (Legge et al., 2019; 
Wimberley et al., 2016), lifetime drug abuse (Wimberley et al., 2016), poorer premorbid 
social adjustment (Legge et al., 2019) and living in less urban area (Legge et al., 2019). 
Decreased plasma level of antipsychotic drugs have also been associated with TR 
(McCutcheon et al., 2018), suggesting that adherence and pharmacokinetic factors need to be 
addressed when investigating TR. 
In the current study, we aimed to determine the potential of PRS-SZ to explain the 
heterogeneity in treatment response in a large, naturalistic sample of patients with 
schizophrenia spectrum disorders using the most recent consensus criteria for defining 




TR associated with increasing PRS-SZ and thus overlapping mechanisms for schizophrenia 
and TR. Additionally we investigated previous suggested non-genetic predictors of TR such 
as earlier age at onset, lifetime drug abuse and family history of psychosis (Frank et al., 2015; 
Legge et al., 2019; Meltzer et al., 1997; Wimberley et al., 2016). We also investigated dose 
serum ratio of antipsychotic medication in relation to TR, serving to account for non-
adherence as a possible confounder and drug turnover as a possible contributor in TR 
mechanism. 
2. Methods 
2.1 Participants  
As part of the Thematically Organized Psychosis (TOP) study, participants (N=321) were 
included in the current study if they fulfilled diagnostic criteria for a schizophrenia spectrum 
disorder, defined as schizophrenia (N=195), schizophreniform disorder (N=5), schizoaffective 
disorder (N=66), psychosis not otherwise specified (N=39), brief psychotic disorder (N=2) or 
delusional disorder (N=14). Patients were recruited to the TOP study from the mental health 
clinics of the major hospitals in Oslo, currently covering a catchment area of close to 700 000 
inhabitants. All patients were between 18-65 years of age and able to provide consent of 
participation. Patients were excluded if they had a history of severe somatic disease 
interfering with brain functioning including neurological disease, history of moderate or 
severe head trauma, or an IQ below 70. Participants recruited during their first psychotic 
episode were excluded from the current study as they were in the initial phase of antipsychotic 
drug trials. Demographic data, information about ancestry and information about current and 
past five years drug treatment were collected by interview and from medical records, as was 
information on duration, adherence and adverse effects of the treatment. See table 1 for 
details. 




2.2.1 Clinical assessment  
Diagnostics were made by using the Structured Clinical Interview (SCID-1) (M.B. First, 
1995) for the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV (American 
Psychiatric Association, 2000). Symptoms of psychosis were assessed using the Positive and 
Negative Syndrome Scale (PANSS) (Kay et al., 1987) and function was assessed using the 
Global Assessment of Functioning (GAF-F) scale (Endicott et al., 1976). Previous psychiatric 
history was recorded based on interviews and medical records. Diagnostic interviews were 
performed by psychologists and physicians supervised by a senior professor in psychiatry. 
The research personnel are all comprehensively trained for the interviews based on a UCLA 
training program (Ventura et al., 1998). 
2.2.2 Treatment Resistant Schizophrenia (TR) classification  
Patients were classified as being TR or non-TR; the classification was adapted for 
retrospective data based on the Treatment Response and Resistance in Psychosis (TRRIP) 
working group’s consensus criteria (Howes et al., 2017).  A patient was defined as being TR 
based on (during the five years prior to inclusion) either 1) history of treatment with clozapine 
or 2) two or more failed trials of antipsychotic treatment, each of at least six weeks duration 
and with therapeutic dosage. At least one of the antipsychotics had to be a second generation 
antipsychotic. Previous trials were classified as failed if there were change in antipsychotic 
agents. The current trial was classified as failed if the patient had significant symptoms (a few 
patients had frequent psychotic episodes [five or more during the five years] and were thus 
classified as TR regardless of current symptoms). Current significant symptoms were defined 
as at least one score of at least moderate severity on the PANSS positive subscale together 
with a score of 60 or less on the GAF functioning scale (GAF-F), indicating at least 
moderately impaired functioning (Howes et al., 2017). The antipsychotic treatment was not 




drugs used for indications other than psychosis, typically as needed for sleep or anxiety, did 
not count as a trial of antipsychotic treatment (see supplementary table). Patients having used 
a third, or more, antipsychotic drugs during the last five years after the two initial trials, were 
classified as having treatment resistance regardless of ongoing symptoms. We did not apply 
any limitation on the maximum duration of an antipsychotic trial. Based on the criteria, both 
patients currently in remission and patients with psychotic symptoms could be classified as 
TR. Patients not fulfilling the criteria for TR were classified as non-TR. According to this 
definition, 108 patients (33.6 %) were classified as having treatment resistance in our sample. 
See table 1 for details. 
2.3 Polygenic Risk Score for Schizophrenia 
DNA was extracted from blood and saliva samples collected in the clinic. Genotyping was 
performed on Human Omni Express-24 v.1.1 (Illumina Inc., San Diego, CA, USA) at 
deCODE Genetics (Reykjavik, Iceland). Quality control was performed using PLINK 1.9 
(Purcell et al., 2007). Briefly, variants were excluded if they had low coverage (<95%), had 
low minor allele frequency (MAF) (<0.01), deviated from Hardy-Weinberg equilibrium 
(p<10-4), or occurred at significantly different frequencies in different genotyping batches 
(FDR<0.5). Whole individual genotypes were excluded if they had low coverage (less than 
95%) or high likelihood of contamination (heterozygosity above mean + 5 standard 
deviations). MaCH software (Das et al., 2016; Li et al., 2010) was used to impute the 
genotypes of all participants onto reference haplotypes derived from samples of European 
ancestry in the 1000 Genome Project (genomic build GRCh37). The PRS-SZs were based on 
a meta-analysis of all Psychiatric Genomics Consortium Schizophrenia Working Group’s 
genome-wide association sub-studies except TOP (Schizophrenia Working Group of the 
Psychiatric Genomics Consortium, 2014), which included patients with schizophrenia and 




that met any of the following conditions: MAF<0.05; imputation quality (ratio between 
observed and expected allelic variance) <0.8; not present in more than half of the sub-studies. 
Variants from the MHC region were also excluded. The remaining variants were clumped into 
independent regions on the basis of the linkage disequilibrium structure of the 1000 Genomes 
Phase III European population. PLINK v1.9 was used with the following parameters: --
clump-p1 1.0 --clump-p2 1.0 --clump-r2 0.2 --clump-kb 500. The allelic dosage coefficients 
(or logarithms of the odds ratios) of the variants with minimum p-values from all independent 
regions were used in constructing the PRS-SZs. These were calculated for all individuals 
following Purcell et al’s (2009) recipe of multiplying the number of effect alleles they carried 
by the allelic dosage coefficients calculated in the meta-analysis. Only European subjects 
were included in our sample to avoid confounding from population stratification. 
2.4 Medication and serum levels 
Blood was withdrawn from antecubital vein in the morning for assessments of antipsychotic 
drug serum level by methods previously described (Steen et al., 2017). Standardised 
relationships between dose and serum level of antipsychotics were calculated to enable the 
comparison of several antipsychotic drugs: First, the dose of each participant’s primary 
antipsychotic drug was divided by the Defined Daily Dose (DDD) (Leucht et al., 2016) of the 
drug to obtain a standardised dose for each participant. Second, the measured serum level of 
this antipsychotic drug was divided by the median of the antipsychotic drug’s reference range 
(Hiemke et al., 2018). Finally, the standardised dose was divided by the standardised serum 
level, to obtain a relationship between dose and serum level comparable across antipsychotics 





All participants gave written consent of participation after a written and oral description of the 
study. The study was approved by The Regional Ethics Committee, The Norwegian Data 
Inspectorate, and the Norwegian Directorate of Health approved the biobank. 
2.6 Statistical analyses  
All statistical analyses were performed using the Statistical Package for the Social Sciences 
(SPSS Inc, Chicago II, version 24). To investigate differences in demographic and clinical 
variables we used chi-square tests for the categorical variables, independent sample t-test for 
normally distributed continuous variables and Mann Whitney U test for non-parametric 
distributions. Normality was assessed with Q-Q-plots, histograms and Kolmogorov-Smirnov 
statistics. Potential issues with multicollinearity and outliers in the regression analyses were 
ruled out. To assess the association of PRS-SZ with TR we used binary logistic regression. 
Patients were coded as either TR or non-TR and this binary variable was set as the dependent 
variable. The standardised PRS for schizophrenia (PRS-SZ) was set as the predictor variable 
with adjustments for ancestry (using the twelve first genetic principal components giving the 
highest classification correctness of TR and non-TR in the statistical model), and for 
genotyping batch (7 batches) in addition to age at inclusion and sex (main model). 
Adjustments for time since first episode of the disorder and for time since first drug treatment 
were also tested. Regression analyses were performed with PRS-SZs based on different SNP 
significance thresholds (Wimberley et al., 2017; Zhang et al., 2019), due to testing of five 
inclusion thresholds, we applied a Bonferroni-corrected significance level of p<0.01 for the 
effect of PRS-SZ. Secondary logistic regression analyses with the significantly associated 
PRS-SZ were performed by additionally adjusting for all the included diagnoses first, and 
then including season of birth (summer versus winter) and dose serum ratio, separately. 
Spearman’s rho was applied to quantify the correlation between PRS-SZ and PANSS-total to 




PRS-SZ and GAF-F. Spearman’s rho was also calculated to confirm the correlation between 
PRS-SZ at different thresholds. We also performed an additional logistic regression analysis 
after excluding all clozapine users to rule out a specific association with clozapine use, as well 
as a regression analysis without PRS-SZ to demonstrate the contribution of PRS-SZ to the 
model. Finally, we ran the same analysis including only the subgroup of patients with a 
schizophrenia diagnosis. 
3. Results 
3.1 Study sample, demographic and clinical variables 
A diagnosis of schizophrenia was more frequent in the TR group than in the non-TR group 
(p<0.05) and the prevalence of delusional disorder was lower in the TR group than the non-
TR group (p<0.01). Current use of anticonvulsants and lithium was significantly higher in the 
TR group (p<0.05). The positive (p<0.001), negative (p<0.05) general (p<0.05) and total 
(p<0.01) PANSS scores were higher and the GAF-functioning score was lower (p<0.001) in 
the TR group compared to the non-TR group. Winter birth was less common in TR (p<0.05), 
and the dose serum ratio was higher in TR (p<0.05). Drug abuse and family history of 
psychosis only showed a trend level difference (p=0.07 and p=0.09 respectively). See table 1 
for details. 
3.2 PRS-SZ and the relationship to TR 
Higher PRS–SZ was significantly associated with TR-status (p=0.003, odds ratio 1.5[95% CI: 
1.148-1.973], Omnibus test= (21, N=321, 35.77, p=0.023), figure 1 shows unadjusted data) in 
schizophrenia spectrum disorders when applying a significance threshold of p=0.01 for 
inclusion in PRS-SZ. The statistical model yielded a sensitivity of 29.6% and a specificity of 
90.6%, corresponding to a correct classification of 70.1% of cases as TR or non-TR. The 
positive predictive value was 61.5% (correctly predicted TR) and the negative predictive 




with PRS-SZ, age, sex, batch number and principal components 1-12 was 14.6% 
(Nagelkerke’s pseudo R2). The variance explained by the model without PRS-SZ, batch 
number and principal components was 1.7% (Nagelkerke’s pseudo R2). Table 2 contains the 
classification statistics for the main model. PRS-SZ was significantly associated to TR also 
after adjustments for time since first episode of the disorder and for time since first drug 
treatment, respectively. When excluding all clozapine users (N=21), the PRS-SZ effect on TR 
remained significant (p=0.007), with the model explaining 15.9% (Nagelkerke’s pseudo R2) 
of the variance and correctly classifying 71.7% of all cases. When adjusting for diagnosis, 
PRS-SZ was still associated with TR (p=0.005, odds ratio 1.5[95% CI: 1.128-1.963], with the 
model explaining 24.5% (Nagelkerke’s pseudo R2) of the variance and still correctly 
classifying 71.7%. Season of birth was statistically significant (p=0.05; PRS-SZ remained 
significant, p=0.004). Dose serum ratio did not have significant effect when added to the 
regression model (p=0.653). PRS-SZ based on other GWAS p-value thresholds were not 
significantly associated with TR (GWAS p-value thresholds of p=5x10-8, p=0.05, p=0.1 and 
p=0.5 yielded p-values of 0.649, 0.074, 0.963 and 0.458, respectively, see table 3), the only 
exception being those based on p=0.05 in the secondary statistical model with adjustments for 
diagnosis and season of birth (p=0.047). There were no significant correlations between PRS-
SZ and PANSS-total or GAF-F. By excluding age from the analyses, PRS-SZ was still 
significant, but the Omnibus test of the main model and season of birth in the secondary 
analysis became trend level significant (both p=0.063). The association between PRS-SZ and 
TR remained significant (p=0.018, OR 1.6 [95% CI: 1.079-2.253]) when analysing only 
patients with a schizophrenia diagnosis (N=195). There was a strong and significant (p<0.01) 
correlation between PRS-SZ at the different thresholds. 




In the current study, we found PRS-SZ at p=0.01 to be significantly associated with 
antipsychotic drug TR in patients with a schizophrenia spectrum disorder. This indicates PRS-
SZ as a potential biological marker of TR and supports earlier assumptions of genetic factors 
involved in TR. The findings indicate genetic mechanisms in common for schizophrenia and 
TR. Season of birth was significantly associated with TR, also when adjusting for PRS-SZ 
and diagnosis. Associations to PRS-SZs based on other GWAS significance thresholds were 
non-significant, suggesting the current threshold as the most suitable for TR prediction 
(Zhang et al., 2019).  
The current main finding is in line with previous findings of a higher likelihood of responding 
to treatment among first-episode psychosis patients with a low PRS-SZ (Zhang et al., 2019), 
indicating PRS-SZ as a biological marker regardless of duration of illness. An important 
strength of our sample is the inclusion of patients with a well-established diagnosis and with a 
higher likelihood to have received several trials of antipsychotics beyond the initial 
antipsychotic treatment (Haddad and Correll, 2018), assuring the validity of the effect of PRS-
SZ on TR in schizophrenia spectrum disorders. Our finding is also in line with the increased 
PRS-SZ observed in patients with a history of clozapine treatment compared to patients with 
no such history (Frank et al., 2015). 
TR status in our sample was based on the most recent consensus definition criteria (Howes et 
al., 2017), yielding a TR rate of 33.6%. Contrary to the current study, several other studies 
have restricted the definition of TR to involving clozapine use, which may limit the 
representativeness of the TR sample (Howes et al., 2017; Kelly et al., 2010). The three studies 
that did not find significant association between PRS-SZ and TR (Legge et al., 2019; Martin 
and Mowry, 2016; Wimberley et al., 2017) also used definitions of treatment-resistance 
somewhat different from those following the recent consensus-based criteria (Howes et al., 




hospitalization during antipsychotic treatment within 18 months after at least two periods of 
different antipsychotic monotherapy, thus introducing hospitalization as a criterion. 
According to their definition, 21% of the patients were defined as TR during follow-up, which 
is below the general estimate of 30-40% (Elkis, 2007; Gillespie et al., 2017; Kane et al., 
2019). The definition used by Martin and Mowry (2016), based on clinical features and 
course, resulted in a TR prevalence of 37.09%, more like ours. In the study by Legge et al. 
(2019), TR was defined as either rating negatively on the Operational Criteria Checklist 
(OPCRIT) item 89 or receiving clozapine treatment, resulting in a TR prevalence of 52.4%. 
The authors explain the high frequency of TR as due to recruitment from clozapine clinics. 
They also used a more general criterion from the Operational Criteria Checklist for Psychotic 
Illness and Affective Illness to decide TR classification. Their sample might thus be less 
representative of TR (Howes et al., 2017; Kelly et al., 2010) than the present naturalistic 
sample. The lack of consistence in TR definition criteria could contribute to the varying 
results with regard to a PRS-TR association. The inconsistent findings could also be due to 
the use of GWAS of smaller samples (Frank et al., 2015). 
The current study comprises a naturalistic sample with TR based on the most recent 
consensus criteria and a TR rate comparable with the generally reported prevalence (Elkis, 
2007; Gillespie et al., 2017; Kane et al., 2019). It is however possible that some of the current 
associations could be due to overlap between TR characteristics and illness severity. If the 
cohorts analysed in the GWAS included mostly chronic patients with more severe illness, one 
could speculate that the PRS-SZ association exists because individuals with TR tends to be 
more severely ill. Attempting to test this possibility, we performed a sub-analysis using the 
same model but excluding all clozapine users. In this analysis, we found effects similar to 
those found in the main analysis. Moreover, there were no significant correlations between 




Season of birth was significantly associated with TR, in line with one previous study showing 
a lower prevalence of winter births in TR (Wimberley et al., 2016). The effect remained 
significant after adjustment for PRS-SZ, suggesting the existence of genuine effects unrelated 
to the genetics of the disorder, indicating the complexity of TR. Considering the increased 
prevalence of winter or spring births in schizophrenia (Davies et al., 2003), the finding 
supports the hypothesis of TR being a categorically distinct subgroup (Gillespie et al., 2017). 
It has been suggested that the TR group represents a more “genuine schizophrenia” with 
differences in response potentially representing genetic and sociocultural factors (Itil et al., 
1966). Several subsequent studies have supported this hypothesis (Frank et al., 2015; 
Gillespie et al., 2017; Joober et al., 1999; Wolkin et al., 1989). Studies exploring the 
mechanisms of TR have reported a lower level of striatal dopamine synthesis capacity 
(Demjaha et al., 2012) as well as higher levels of glutamate in the anterior cingulate cortex 
(Demjaha et al., 2014). Significant interactions between dopamine transporter variable 
number tandem repeats (DAT-VNTR) and the serotonin transporter (SERT)-in2 
polymorphism are also reported in TR (Bilic et al., 2014). Further, a strong association was 
found between TR and the variants for brain derived neurotrophic factor (BDNF), which is 
associated with schizophrenia (Di Carlo et al., 2019) and interacts with monoaminergic 
neurotransmitters (Zhang et al., 2013). Moreover, an increased number of rare copy number 
variants (CNV) are associated with TR (Martin and Mowry, 2016). This is in line with the 
current findings of TR linked to the genetics of schizophrenia (Owen et al., 2016). 
Furthermore, the current association between TR and PRS-SZ might indicate underlying 
factors in TR, as recent studies have revealed genetic pleiotropy between schizophrenia and 
phenotypes such as brain structure volumes (Terwisscha van Scheltinga et al., 2013; Smeland 
et al., 2018; Chen et al., 2019), immune related conditions (Andreassen et al., 2015) body 




related to antipsychotic drug treatment response (Barry et al., 2019; Hutcheson et al., 2014; 
Noto et al., 2015; Pillinger et al., 2020). 
The current study has several strengths. Our large, well-characterized sample enabled the 
application of criteria for TR well matching the most recent consensus-criteria, resulting in a 
TR rate in accordance with the literature (Elkis, 2007; Gillespie et al., 2017; Kane et al., 2019) 
and demonstrating associations to PRS-SZ and demographic data. We did not find any 
mediating effect of diagnosis. The naturalistic design assures relevance to clinical samples, 
with the current results being of special interest for treatment response in long-term and thus 
the long-term prognosis, as opposed to studies of first-episode patients with a different 
response patterns to antipsychotic medication (Haddad and Correll, 2018). The limitations 
include the cross-sectional design, which made us unable to assess actual reduction of 
symptoms during antipsychotic medication and therefore to implement the criterion of lack of 
20% reduction of symptoms (Howes et al., 2017). This could lead to classification bias as 
some patients being classified as TR due to fulfilling symptom criteria might have 
experienced a 20% reduction of symptoms during the present trial and hence should have 
been classified as non-TR. Moreover, although previous antipsychotic administrations were 
adequate in dosage and duration, we lack serum concentration data, and cannot exclude issues 
with adherence during these previous trials. However, thanks to our detailed protocol, we 
were still able to adapt the prospective based criteria to match the TR rates shown previously 
(Elkis, 2007; Gillespie et al., 2017; Lally et al., 2016), and confirm the PRS-SZ effect in the 
clozapine-free subsample. By excluding first-episode patients and missing out on individuals 
that did not survive long enough to be included in the study, we might have failed to include 
patients with a fast recovery or severe illness, decreasing the power and variability of the data. 
Moreover, we cannot fully exclude this as a source of bias, although there were no significant 




symptoms would not have affected the results. Various strategies may be applied for choosing 
PRS-SZ threshold values (Wimberley et al., 2017; Wray et al., 2014) and there exists no well-
founded procedure; however, the thresholds selected in the current study have been used 
previously (Zhang et al., 2019) and results for all of them were reported. Moreover, the results 
were strictly adjusted for the number of levels analysed. The reason why only threshold 
p=0.01 results in a significant association with PRS-SZ is matter for speculation. It might be 
that the PRS-SZ obtained with less stringent thresholds are too unspecific and therefore 
unable to detect the association, while more stringent thresholds exclude variants of 
importance. 
In conclusion, we found an association between PRS-SZ at SNP significance threshold 
p=0.01 and TR in patients with a schizophrenia spectrum disorder, as well as an association 
between season of birth and TR. This indicates an association between PRS-SZ and treatment 
response, although the failure to replicate the findings with other SNP significance thresholds 
makes the association less robust. The findings suggest that TR is related to genetic factors 
that also drive core pathophysiological processes in schizophrenia spectrum disorders, as well 
as to factors independent of schizophrenia genetics. The positive and negative predictive 
values of the current model are not sufficient for clinical use. Still, the study confirms the 
utility of PRS-SZ as a predictive supplement based on forthcoming expansions of GWAS 
data.  
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Figure legends  
Fig. 1. Standardized polygenic risk score (p=0.01) for schizophrenia (y-axis) in patients with  
treatment-resistance (TR) and non-treatment resistance (non-TR), grouped by schizophrenia 



























































*p≤0.05, *p ≤0.05, **p<0.01, ***p< 0.001 
Missing data for Ɨ58, ƗƗ16, ƗƗƗ21, ƗƗƗƗ65 participants. 
Abbreviations: BMI = Body Mass Index; GAF-F = Global Assessment of Functioning, functioning scale; IQR = 
Interquartile range; N = Number; NOS = Not otherwise specified; PANSS: Positive and Negative Syndrome Scale; SD = 











  TR, N (%)=108 (33.6)    Non-TR, N (%)=213 (66.4)  
Sex female, N (%) 51 (47.2)                                 103 (48.4) 
Age, median (IQR)                            31 (12)                                      34 (18) 
BMI, median (IQR)ᶧ                           25 (6.4)                                  24.5 (4.7) 
Age at onset, median (IQR) 
Season of birth (Des-March), N (%) 
Family history of psychosis, N (%) 
                           22.5 (9) 
    26 (24.1)* 
                       30 (21.4) 
                                     23 (13) 
                                  76 (35.7) 
                                  44 (30.3)           
PANSS-total, median (IQR)                       60 (19)**                                      56 (23) 
PANSS-positive, median (IQR)  15 (7)***                                         12 (7) 
PANSS-negative, median (IQR)                            14 (7)*                                         12 (9) 
PANSS-general, median (IQR)                          31 (10)*                                      29 (11) 
GAF-F, median (IQR)    41 (13)***                                       45 (13) 






Delusional disorder  
 
 74 (68.5)* 
                               0 (0) 
 26 (24.1) 
                            8 (7.4) 
                               0 (0) 
 0 (0)** 
 
                                121 (56.8) 
                                      5 (2.3) 
                                  40 (18.8) 
                                  31 (14.6) 
                                      2 (0.9) 
                                    14 (6.6) 
Medication, N (%) 
Antipsychotics 
Antidepressants 
Anticonvulsants and Lithium 
 
 102 (94.4) 
 28 (25.9) 
 28 (25.9)* 
 
   188 (88.3) 
 71 (33.3) 
 33 (15.5)  
Time since first episode, median years 
(IQR)ƗƗ 
9 (8.8) 9 (11) 
Time since first medical treatment, 
median years (IQR)ƗƗƗ 
6 (7) 5 (9) 
Lifetime drug abuse, N (%)  27 (25)  35 (16.4) 
Lifetime alcohol abuse, N (%)  14 (13)  25 (11.7) 
Inpatient when first diagnosed, N (%)  48 (51.6)                                       80 (50) 








aThe model included polygenic risk score, sex, age, principal components 1-12, batch number (independent variables) 
and Treatment-resistance and non-Treatment resistance (dependent variable), bSensitivity, cSpecificity, dPositive 






















 TR (N) Non-TR (N)  
TR (N) 32 20 61.5%d 
Non-TR (N) 76 193 71.7%e 














Table 3. Association between PRS-SZ and treatment resistance with different SNP 






aOdds ratio (OR) given with 95% confidence interval 
bExplained variance (Nagelkerke pseudo R2) of the unadjusted/adjusted model  
Abbreviations: GWAS= Genome-Wide Association Study, PRS-SZ= Polygenic Risk Score for Schizophrenia, SNP= 



















PRS-SZ aUnadjusted aAdjusted bModel R2  
GWAS p=0.541, OR=0.9 (0.737-1.173) p=0.649, OR=0.9 (0.741-1.205) 0.2/10.7 
0.01 p=0.007, OR=1.4 (1.092-1.768) p=0.003, OR=1.5 (1.148-1.973) 3.2/14.6 
0.05 p=0.094, OR=1.3 (0.962-1.645) p=0.074, OR=1.3 (0.974-1.788) 1.2/11.9 
0.1 p=0.977, OR= 1.0 (0.780-1.291) p=0.963, OR=1.0 (0.748-1.320) 0.0/10.6 
0.5 p=0.566, OR=1.1 (0.824-1.423) p=0.458, OR=1.1 (0.823-1.542) 0.1/10.8 
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